Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
University of Alabama at Birmingham
Mayo Clinic
Thomas Jefferson University
University of Pittsburgh
Stanford University
Stanford University
Pfizer
National Institutes of Health Clinical Center (CC)
Sorrento Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
4SC AG
Fred Hutchinson Cancer Center
Moleculin Biotech, Inc.
Barbara Ann Karmanos Cancer Institute
miRagen Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Acrotech Biopharma Inc.
Acrotech Biopharma Inc.
University of Wisconsin, Madison
Virginia Commonwealth University
Northwestern University
Mayo Clinic
Case Comprehensive Cancer Center
Swiss Cancer Institute
City of Hope Medical Center
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Louisville
Alliance for Clinical Trials in Oncology
Progen Pharmaceuticals